Pages

Search This Website

Saturday, 9 January 2021

Vaccination will start in the country from January 16

Moment after vaccination:Vaccination will start in the country from January 16, 30 million people will be vaccinated in the first phase





The corona vaccination program across the country will start from January 16, i.e. after the completion of Kamurta. The government made the announcement on Saturday. Initially, the vaccine will be given to health workers and frontline workers, numbering 30 million.

 The second phase will be given to people above 50 years of age and the third phase will be given to people below 50 years of age suffering from serious illnesses. About 270 million people will be vaccinated in the second and third phases.

Modi meeting to obtain information on preparations
to be meeting Prime Minister Narendra Modi on Saturday hailevala koronani to review the situation in the country. He also reviewed the states ’preparations for vaccination. The meeting was also attended by the Cabinet Secretary, Principal Secretary, Health Secretary and other senior officials.

Two vaccines approved in the
country Two vaccines have been approved for emergency use in the country, including Covishield of Serum Institute of India (SII) and Covacin of Bharat Biotech. The government has announced transportation guidelines for delivering both vaccines to different parts of the country.




What is so special about Kovishield?


Analysis of Covishield's clinical trials has yielded very good results. Volunteers were given first half dose and then full dose. No one has had any serious health problems after taking this dose.

EFC remained 90% when half doses were given. Only a month later he was given the full dose. EFC was 62% when both were given full dose.


The average EFC in both doses was 70%. All the results are statistically special. Volunteers will be tested for blood samples and immunogenicity for one year after vaccination to find out the EFC. Samples are being taken every week to check for infection.

No comments:

Follow Us